ATXS
Astria Therapeutics, Inc.
Price Chart
No historical data available
Latest Quote
$12.58
Current Price| Day High | $12.59 |
| Day Low | $12.45 |
Stock Information
| Shares Outstanding | 57.08M |
| Total Debt | $4.46M |
| Cash Equivalents | $227.72M |
| Revenue | $706K |
| Net Income | $-124.03M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $718.13M |
| EPS (TTM) | $-2.14 |
| Exchange | NGM |
Recent Price History
No history data available. Data will be fetched automatically.
About Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts. As of January 23, 2026, Astria Therapeutics, Inc. operates as a subsidiary of BioCryst Pharmaceuticals, Inc.
đ° Latest News
BioCryst (BCRX) Is Up 9.5% After Astria Deal And HAE Data Spotlight Has The Bull Case Changed?
Simply Wall St. âĸ 2026-02-25T10:12:23Z
Evercore ISI Sees Long-Term Growth Potential For BioCryst Pharmaceuticals, Inc. (BCRX) Following Astria Acquisition
Insider Monkey âĸ 2026-02-23T21:42:37Z
BioCryst Acquisition Of Astria Highlights Rare Disease Focus And Valuation Gap
Simply Wall St. âĸ 2026-02-07T21:04:36Z
Jim Cramer on BioCryst Pharmaceuticals: âJust Stay Away From Thatâ
Insider Monkey âĸ 2026-02-07T05:56:54Z
BioCryst Pharmaceuticals Face Numerous Important Catalysts in 2026, Wedbush Says
MT Newswires âĸ 2025-12-30T12:22:46ZWhy Analysts Say the BioCryst Story Is Changing After Astria Therapeutics Acquisition
Simply Wall St. âĸ 2025-11-12T22:16:29Z
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates
Zacks âĸ 2025-11-12T14:10:01Z
BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock?
Zacks âĸ 2025-10-16T11:56:00Z
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX
Zacks âĸ 2025-10-15T14:05:00Z
BioCryst to buy Astria Therapeutics for $700m in enterprise value
Pharmaceutical Technology âĸ 2025-10-15T09:16:29Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $111,558,000 | $67,831,000 | $53,503,000 | $30,359,000 |
| Other Income Expense | $-62,000 | $-15,261,000 | $-55,000 | $-164,675,000 |
| Other Non Operating Income Expenses | $-62,000 | $-62,000 | $-55,000 | $-58,000 |
| Net Non Operating Interest Income Expense | $17,360,000 | $10,201,000 | $1,724,000 | $122,000 |
| Operating Expense | $111,558,000 | $67,831,000 | $53,503,000 | $30,359,000 |
| General And Administrative Expense | $34,452,000 | $25,704,000 | $19,239,000 | $14,807,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-94,260,000 | $-72,891,000 | $-51,834,000 | $-194,912,000 |
| Net Interest Income | $17,360,000 | $10,201,000 | $1,724,000 | $122,000 |
| Interest Income | $17,360,000 | $10,201,000 | $1,724,000 | $122,000 |
| Normalized Income | $-94,260,000 | $-57,692,000 | $-51,834,000 | $-30,295,000 |
| Net Income From Continuing And Discontinued Operation | $-94,260,000 | $-72,891,000 | $-51,834,000 | $-194,912,000 |
| Total Operating Income As Reported | $-111,558,000 | $-83,030,000 | $-53,503,000 | $-194,976,000 |
| Net Income Common Stockholders | $-94,260,000 | $-72,891,000 | $-51,834,000 | $-219,349,000 |
| Net Income | $-94,260,000 | $-72,891,000 | $-51,834,000 | $-194,912,000 |
| Net Income Including Noncontrolling Interests | $-94,260,000 | $-72,891,000 | $-51,834,000 | $-194,912,000 |
| Net Income Continuous Operations | $-94,260,000 | $-72,891,000 | $-51,834,000 | $-194,912,000 |
| Pretax Income | $-94,260,000 | $-72,891,000 | $-51,834,000 | $-194,912,000 |
| Special Income Charges | $0 | $-15,199,000 | $0 | $-164,617,000 |
| Interest Income Non Operating | $17,360,000 | $10,201,000 | $1,724,000 | $122,000 |
| Operating Income | $-111,558,000 | $-67,831,000 | $-53,503,000 | $-30,359,000 |
| Per Share | ||||
| Diluted EPS | $-1.68 | $-2.42 | $-3.55 | $-24.58 |
| Basic EPS | $-1.68 | $-2.42 | $-3.55 | $-24.58 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-111,558,000 | $-52,632,000 | $-53,503,000 | $134,258,000 |
| Total Unusual Items | $0 | $-15,199,000 | $0 | $-164,617,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-15,199,000 | $0 | $-164,617,000 |
| EBITDA (Bullshit earnings) | $-111,558,000 | $-67,831,000 | $-53,503,000 | $-30,359,000 |
| EBIT | $-111,558,000 | $-67,831,000 | $-53,503,000 | $-30,359,000 |
| Diluted Average Shares | $56,161,249 | $30,123,316 | $14,620,618 | $8,925,173 |
| Basic Average Shares | $56,161,249 | $30,123,316 | $14,620,618 | $8,925,173 |
| Diluted NI Availto Com Stockholders | $-94,260,000 | $-72,891,000 | $-51,834,000 | $-219,349,000 |
| Research And Development | $77,106,000 | $42,127,000 | $34,264,000 | $15,552,000 |
| Selling General And Administration | $34,452,000 | $25,704,000 | $19,239,000 | $14,807,000 |
| Other Gand A | $34,452,000 | $25,704,000 | $19,239,000 | $14,807,000 |
| Other Special Charges | - | $15,199,000 | - | $164,617,000 |
| Preferred Stock Dividends | - | - | - | $24,437,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $319,263,000 | $243,116,000 | $221,216,000 | $122,311,000 |
| Total Assets | $342,363,000 | $254,666,000 | $230,633,000 | $127,514,000 |
| Total Non Current Assets | $7,720,000 | $3,724,000 | $2,943,000 | $439,000 |
| Other Non Current Assets | $2,606,000 | $3,361,000 | $1,995,000 | $45,000 |
| Current Assets | $334,643,000 | $250,942,000 | $227,690,000 | $127,075,000 |
| Other Current Assets | $6,511,000 | $4,412,000 | $1,253,000 | $1,567,000 |
| Cash Cash Equivalents And Short Term Investments | $328,132,000 | $246,530,000 | $226,437,000 | $125,508,000 |
| Cash And Cash Equivalents | $59,820,000 | $175,530,000 | $20,525,000 | $86,508,000 |
| Cash Equivalents | - | - | $1,944,000 | $1,853,000 |
| Cash Financial | - | - | $18,581,000 | $84,655,000 |
| Prepaid Assets | - | - | - | $1,567,000 |
| Debt | ||||
| Total Debt | $5,353,000 | $329,000 | $939,000 | $365,000 |
| Long Term Debt And Capital Lease Obligation | $3,969,000 | $0 | $357,000 | $0 |
| Current Debt And Capital Lease Obligation | $1,384,000 | $329,000 | $582,000 | $365,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $23,100,000 | $11,550,000 | $9,417,000 | $5,203,000 |
| Total Non Current Liabilities Net Minority Interest | $3,969,000 | $0 | $357,000 | $0 |
| Current Liabilities | $19,131,000 | $11,550,000 | $9,060,000 | $5,203,000 |
| Payables And Accrued Expenses | $12,663,000 | $7,174,000 | $5,105,000 | $2,880,000 |
| Payables | $4,320,000 | $1,513,000 | $788,000 | $1,557,000 |
| Accounts Payable | $4,320,000 | $1,513,000 | $788,000 | $1,557,000 |
| Equity | ||||
| Common Stock Equity | $223,939,000 | $147,792,000 | $124,818,000 | $25,913,000 |
| Preferred Stock Equity | $95,324,000 | $95,324,000 | $96,398,000 | $96,398,000 |
| Total Equity Gross Minority Interest | $319,263,000 | $243,116,000 | $221,216,000 | $122,311,000 |
| Stockholders Equity | $319,263,000 | $243,116,000 | $221,216,000 | $122,311,000 |
| Gains Losses Not Affecting Retained Earnings | $163,000 | $0 | $-79,000 | $0 |
| Other Equity Adjustments | $163,000 | - | $-79,000 | - |
| Retained Earnings | $-674,794,000 | $-580,534,000 | $-507,643,000 | $-455,809,000 |
| Other | ||||
| Ordinary Shares Number | $56,434,219 | $41,034,797 | $27,501,340 | $13,016,955 |
| Share Issued | $56,434,219 | $41,034,797 | $27,501,340 | $13,016,955 |
| Tangible Book Value | $223,939,000 | $147,792,000 | $124,818,000 | $25,913,000 |
| Invested Capital | $223,939,000 | $147,792,000 | $124,818,000 | $25,913,000 |
| Working Capital | $315,512,000 | $239,392,000 | $218,630,000 | $121,872,000 |
| Capital Lease Obligations | $5,353,000 | $329,000 | $939,000 | $365,000 |
| Total Capitalization | $319,263,000 | $243,116,000 | $221,216,000 | $122,311,000 |
| Additional Paid In Capital | $898,513,000 | $728,285,000 | $632,512,000 | $481,709,000 |
| Capital Stock | $95,381,000 | $95,365,000 | $96,426,000 | $96,411,000 |
| Common Stock | $57,000 | $41,000 | $28,000 | $13,000 |
| Preferred Stock | $95,324,000 | $95,324,000 | $96,398,000 | $96,398,000 |
| Long Term Capital Lease Obligation | $3,969,000 | $0 | $357,000 | $0 |
| Current Capital Lease Obligation | $1,384,000 | $329,000 | $582,000 | $365,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,084,000 | $4,047,000 | $3,373,000 | $1,958,000 |
| Current Accrued Expenses | $8,343,000 | $5,661,000 | $4,317,000 | $1,323,000 |
| Net PPE | $5,114,000 | $363,000 | $948,000 | $394,000 |
| Gross PPE | $5,114,000 | $363,000 | $948,000 | $394,000 |
| Other Properties | $5,114,000 | $363,000 | $948,000 | $394,000 |
| Other Short Term Investments | $268,312,000 | $71,000,000 | $205,912,000 | $39,000,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-81,537,000 | $-68,470,000 | $-43,624,000 | $-30,172,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-81,212,000 | $-68,445,000 | $-43,533,000 | $-30,151,000 |
| Cash Flow From Continuing Operating Activities | $-81,212,000 | $-68,445,000 | $-43,533,000 | $-30,151,000 |
| Operating Gains Losses | - | - | $1,542,000 | $71,000 |
| Investing Activities | ||||
| Capital Expenditure | $-325,000 | $-25,000 | $-91,000 | $-21,000 |
| Investing Cash Flow | $-191,863,000 | $135,052,000 | $-167,129,000 | $-12,555,000 |
| Cash Flow From Continuing Investing Activities | $-191,863,000 | $135,052,000 | $-167,129,000 | $-12,555,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $152,417,000 | $87,978,000 | $144,637,000 | $104,261,000 |
| Financing Cash Flow | $157,202,000 | $88,398,000 | $144,721,000 | $104,284,000 |
| Cash Flow From Continuing Financing Activities | $157,202,000 | $88,398,000 | $144,721,000 | $104,284,000 |
| Net Common Stock Issuance | $152,417,000 | $87,978,000 | $144,637,000 | $104,261,000 |
| Common Stock Issuance | $152,417,000 | $87,978,000 | $144,637,000 | $104,261,000 |
| Other | ||||
| End Cash Position | $59,820,000 | $175,693,000 | $20,688,000 | $86,629,000 |
| Beginning Cash Position | $175,693,000 | $20,688,000 | $86,629,000 | $25,051,000 |
| Changes In Cash | $-115,873,000 | $155,005,000 | $-65,941,000 | $61,578,000 |
| Proceeds From Stock Option Exercised | $4,785,000 | $420,000 | $84,000 | $23,000 |
| Net Investment Purchase And Sale | $-191,538,000 | $135,077,000 | $-167,038,000 | $-19,000,000 |
| Sale Of Investment | $4,053,000,000 | $2,059,500,000 | $229,026,000 | $59,000,000 |
| Purchase Of Investment | $-4,244,538,000 | $-1,924,423,000 | $-396,064,000 | $-78,000,000 |
| Net PPE Purchase And Sale | $-325,000 | $-25,000 | $-91,000 | $-21,000 |
| Purchase Of PPE | $-325,000 | $-25,000 | $-91,000 | $-21,000 |
| Change In Working Capital | $4,543,000 | $-2,413,000 | $2,647,000 | $-3,877,000 |
| Change In Other Current Liabilities | $-731,000 | $-610,000 | $574,000 | $-681,000 |
| Change In Payables And Accrued Expense | $6,526,000 | $2,743,000 | $3,641,000 | $-3,281,000 |
| Change In Accrued Expense | $3,719,000 | $2,018,000 | $4,407,000 | $-1,316,000 |
| Change In Payable | $2,807,000 | $725,000 | $-766,000 | $-1,965,000 |
| Change In Account Payable | $2,807,000 | $725,000 | $-766,000 | $-1,965,000 |
| Change In Prepaid Assets | $-1,252,000 | $-4,546,000 | $-1,568,000 | $85,000 |
| Other Non Cash Items | $1,074,000 | $631,000 | $-442,000 | $165,205,000 |
| Stock Based Compensation | $13,042,000 | $6,314,000 | $4,554,000 | $3,362,000 |
| Amortization Of Securities | $-5,611,000 | $-86,000 | - | - |
| Net Income From Continuing Operations | $-94,260,000 | $-72,891,000 | $-51,834,000 | $-194,912,000 |
| Net Business Purchase And Sale | - | - | $0 | $6,466,000 |
| Sale Of Business | - | - | $0 | $6,466,000 |
| Gain Loss On Investment Securities | - | - | $1,542,000 | $71,000 |
| Change In Other Current Assets | - | - | - | $-109,000 |
Fetched: 2026-02-02